IDEAYA Biosciences Inc
IDYA25.020USD
+0.520+2.12%
收盘 07/28, 16:00（美东）报价延迟15分钟
2.19B总市值
亏损市盈率 TTM
关于 IDEAYA Biosciences Inc 公司
IDEAYA Biosciences, Inc. 是一家精准医疗肿瘤学公司。该公司致力于发现和开发针对使用分子诊断选择的患者群体的靶向疗法。其主要候选产品是 darovasertib (IDE196)、IDE397、IDE161 和 GSK101 (Pol Theta Helicase)。IDE196 是一种小分子蛋白激酶 C (PKC) 抑制剂，与在研 cMET 抑制剂克唑替尼联合使用。IDE397 是其小分子蛋氨酸腺苷转移酶 2a (MAT2A) 抑制剂。IDE161 是其小分子聚（ADP-核糖）糖基水解酶 (PARG) 抑制剂。IDE196 是其临床阶段的 PKC 抑制剂，该公司正在将其评估为合成致死联合疗法。IDE397 是一种 MAT2A 抑制剂，用于治疗具有 MTAP 缺失的实体瘤患者。 IDE161 是其临床阶段的强效选择性 PARG 小分子抑制剂，适用于根据基因突变和/或分子特征具有明确生物标志物的肿瘤患者。
公司简介
公司代码IDYA
公司名称IDEAYA Biosciences Inc
上市日期May 23, 2019
成立日期2015
CEOMr. Yujiro S. Hata
员工数量131
证券类型Ordinary Share
年结日May 23
公司地址7000 Shoreline Ct, Suite 350
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编94080
电话16504436209
网址https://www.ideayabio.com/
公司代码IDYA
上市日期May 23, 2019
成立日期2015
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Joshua Bleharski, Ph.D.
Dr. Joshua Bleharski, Ph.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Catherine J. Mackey, Ph.D.
Dr. Catherine J. Mackey, Ph.D.
Independent Director
Independent Director
--
--
Dr. M. Garret Hampton, Ph.D.
Dr. M. Garret Hampton, Ph.D.
Independent Director
Independent Director
--
--
Dr. Terry J. Rosen, Ph.D.
Dr. Terry J. Rosen, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Darrin Beaupre, M.D., Ph.D.
Dr. Darrin Beaupre, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Independent Director
Independent Director
--
--
Mr. Andres Ruiz Briseno, CPA
Mr. Andres Ruiz Briseno, CPA
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
--
--
Dr. Michael A. White, Ph.D.
Dr. Michael A. White, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
Mr. Yujiro S. Hata
Mr. Yujiro S. Hata
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Joshua Bleharski, Ph.D.
Dr. Joshua Bleharski, Ph.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Catherine J. Mackey, Ph.D.
Dr. Catherine J. Mackey, Ph.D.
Independent Director
Independent Director
--
--
Dr. M. Garret Hampton, Ph.D.
Dr. M. Garret Hampton, Ph.D.
Independent Director
Independent Director
--
--
Dr. Terry J. Rosen, Ph.D.
Dr. Terry J. Rosen, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Darrin Beaupre, M.D., Ph.D.
Dr. Darrin Beaupre, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Independent Director
Independent Director
--
--
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2024
FY2024Q4
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
业务USD
名称
营收
占比
WRN
7.00M
0.00%
MAT2A
0.00
0.00%
Pol Theta
0.00
0.00%
地区USD
名称
营收
占比
United States
7.00M
100.00%
业务
地区
业务USD
名称
营收
占比
WRN
7.00M
0.00%
MAT2A
0.00
0.00%
Pol Theta
0.00
0.00%
股东统计
更新时间: 7月1日 周二
更新时间: 7月1日 周二
持股股东
股东类型
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
14.99%
BlackRock Institutional Trust Company, N.A.
8.17%
Janus Henderson Investors
7.31%
The Vanguard Group, Inc.
5.80%
Federated Hermes Global Investment Management Corp.
5.44%
Other
58.29%
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
14.99%
BlackRock Institutional Trust Company, N.A.
8.17%
Janus Henderson Investors
7.31%
The Vanguard Group, Inc.
5.80%
Federated Hermes Global Investment Management Corp.
5.44%
Other
58.29%
股东类型
持股股东
占比
Investment Advisor
45.54%
Investment Advisor/Hedge Fund
33.49%
Hedge Fund
21.64%
Venture Capital
8.56%
Research Firm
4.37%
Individual Investor
0.91%
Pension Fund
0.77%
Sovereign Wealth Fund
0.59%
Bank and Trust
0.34%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
444
101.86M
116.30%
-6.31M
2025Q1
454
97.81M
111.68%
-11.15M
2024Q4
442
95.26M
108.96%
-7.87M
2024Q3
426
95.20M
112.79%
+2.56M
2024Q2
409
85.26M
112.59%
-3.91M
2024Q1
388
81.45M
108.91%
-1.44M
2023Q4
351
68.31M
105.94%
-512.62K
2023Q3
331
61.92M
105.66%
-3.64M
2023Q2
313
59.35M
103.37%
+5.88M
2023Q1
290
47.36M
97.90%
-6.95M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Fidelity Management & Research Company LLC
13.13M
14.99%
+167.11K
+1.29%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.15M
8.17%
+286.75K
+4.18%
Mar 31, 2025
Janus Henderson Investors
6.40M
7.31%
+544.14K
+9.29%
Mar 31, 2025
The Vanguard Group, Inc.
5.08M
5.8%
+14.54K
+0.29%
Mar 31, 2025
Federated Hermes Global Investment Management Corp.
4.77M
5.44%
-295.60K
-5.84%
Mar 31, 2025
Point72 Asset Management, L.P.
4.41M
5.04%
+4.27M
+3048.93%
Jun 06, 2025
Logos Global Management LP
3.50M
4%
+500.00K
+16.67%
Mar 31, 2025
State Street Global Advisors (US)
3.45M
3.93%
+125.33K
+3.77%
Mar 31, 2025
T. Rowe Price Associates, Inc.
3.39M
3.87%
-395.42K
-10.45%
Mar 31, 2025
Deerfield Management Company, L.P.
3.27M
3.73%
+531.55K
+19.43%
Mar 31, 2025
查看更多
持股ETF
更新时间: 7月6日 周日
更新时间: 7月6日 周日
机构名称
占比
Tema Oncology ETF
1.99%
ALPS Medical Breakthroughs ETF
1.47%
Virtus LifeSci Biotech Clinical Trials ETF
0.88%
SPDR S&P Biotech ETF
0.61%
Direxion Daily S&P Biotech Bull 3X Shares
0.35%
ProShares Ultra Nasdaq Biotechnology
0.21%
Invesco Nasdaq Biotechnology ETF
0.19%
iShares Biotechnology ETF
0.17%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.12%
iShares Russell 2000 Growth ETF
0.12%
查看更多
Tema Oncology ETF
占比1.99%
ALPS Medical Breakthroughs ETF
占比1.47%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.88%
SPDR S&P Biotech ETF
占比0.61%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.35%
ProShares Ultra Nasdaq Biotechnology
占比0.21%
Invesco Nasdaq Biotechnology ETF
占比0.19%
iShares Biotechnology ETF
占比0.17%
JPMorgan BetaBuilders US Small Cap Equity ETF
占比0.12%
iShares Russell 2000 Growth ETF
占比0.12%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
